Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Earnings for Arvinas, Inc. (ARVN)
Earnings in 2023 (TTM): $-363,900,000
According to Arvinas, Inc.'s latest financial reports the company's current earnings (TTM) are $-363,900,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Arvinas, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-363,900,000 | $-367,300,000 |
| 2022 | $-251,000,000 | $-271,900,000 |
| 2021 | $-191,000,000 | $-183,200,000 |
| 2020 | $-119,332,064 | $-111,786,706 |
| 2019 | $-70,292,227 | $-62,132,038 |
| 2018 | $-41,480,466 | $-41,480,466 |
| 2017 | $-24,049,206 | $-24,049,206 |
| 2016 | $-14,438,051 | $-14,350,643 |